Crisaborole topical ointment, 2%: A novel, nonsteroidal, topical antiinflammatory, phosphodiesterase 4 inhibitor: Results from two phase 3 studies treating children and adult patients with mild to moderate atopic dermatitis

2016 ◽  
Vol 74 (5) ◽  
pp. AB86 ◽  
Keyword(s):  
Atopic Dermatitis ◽  
Adult Patients ◽  
Phase 3 ◽  
Two Phase ◽  
Phosphodiesterase 4 ◽  
Phosphodiesterase 4 Inhibitor

scholarly journals 286 Phase 3 studies in atopic dermatitis with the novel, nonsteroidal topical phosphodiesterase 4 inhibitor, crisaborole

2016 ◽  
Vol 136 (5) ◽  
pp. S50 ◽  
Author(s):  
A.S. Paller ◽  
W.L. Tom ◽  
R.S. Call ◽  
L. Eichenfield ◽  
D. Forsha ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
The Novel ◽  
Phase 3 ◽  
Phosphodiesterase 4 ◽  
Phosphodiesterase 4 Inhibitor

28194 Patient-reported outcomes of ruxolitinib cream for the treatment of atopic dermatitis: Pooled results from two phase 3 studies

2021 ◽  
Vol 85 (3) ◽  
pp. AB178
Author(s):  
Eric L. Simpson ◽  
Matthias Augustin ◽  
Diamant Thaçi ◽  
Laurent Misery ◽  
Jonathan I. Silverberg ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Patient Reported Outcomes ◽  
Phase 3 ◽  
Two Phase ◽  
Patient Reported
Sign in / Sign up

Export Citation Format

Share Document